151602-49-2

Basic information

• Product Name: 5-O-DESMETHYL OMEPRAZOLE
• Synonyms: 5-O-DESMETHYL OMEPRAZOLE;5-Desmethylomeprazole;2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-ol;5-O-Desmethyl Omeprazole Discontinued see product # D292120;EsoMeprazole sodiuM iMpurity L;4-Methoxy-2-[[(RS)-(5-hydroxy -1H-benziMidazol-2-yl)sulfinyl]Methyl]-3,5-diMethylpyridine;2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-6-ol;Esomeprazole impurity M
• CAS NO: 151602-49-2
• Molecular Formula: C16H17N3O3S
• Molecular Weight: 331.39
• Product Categories: Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Metabolite Reference Standard
• Mol File: 151602-49-2.mol
• Article Data: 1

Chemical Properties

• Melting Point: 238-240°C
• Boiling Point: 630.5±65.0 °C(Predicted)
• Appearance: /
• Density: 1.46±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Dimethylformamide, Dimethyl Sulfoxide, Ethanol, Methanol
• PKA: 8.71±0.10(Predicted)
• CAS DataBase Reference: 5-O-DESMETHYL OMEPRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-O-DESMETHYL OMEPRAZOLE(151602-49-2)
• EPA Substance Registry System: 5-O-DESMETHYL OMEPRAZOLE(151602-49-2)

Safety Data

• Hazardous Substances Data: 151602-49-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-O-DESMETHYL OMEPRAZOLE is used as an active pharmaceutical ingredient (API) for the development of antiulcerative medications. As a metabolite of Omeprazole, it contributes to the therapeutic effects of the parent drug, helping in the treatment and management of ulcers and related gastrointestinal disorders.
Used in Research and Development:
5-O-DESMETHYL OMEPRAZOLE is used as a research compound for studying the pharmacological properties and mechanisms of action of Omeprazole and its derivatives. This helps in understanding the drug's efficacy, safety, and potential for further development in the treatment of various gastrointestinal conditions.
Used in Quality Control and Standardization:
5-O-DESMETHYL OMEPRAZOLE is used as a reference standard in the quality control and standardization of pharmaceutical products containing Omeprazole. It ensures the accuracy and reliability of analytical methods and helps in maintaining the quality and consistency of the final product.
Used in Drug Metabolism Studies:
5-O-DESMETHYL OMEPRAZOLE is used as a model compound in drug metabolism studies, providing insights into the metabolic pathways and biotransformation processes of Omeprazole in the body. This information is crucial for optimizing drug dosages, understanding drug interactions, and predicting potential side effects.
Used in Drug Synthesis:
5-O-DESMETHYL OMEPRAZOLE can be used as a starting material or intermediate in the synthesis of novel antiulcerative drugs or other related pharmaceutical compounds. Its unique chemical properties make it a valuable building block for the development of new therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 73590-58-6 omeprazole 

Relevant articles and documents

Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes

1. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by 12 recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes have been investigated. 2. Arachidonic acid (50 μM) significantly inhibited CYP1A1- and 1A2-dependent 7-ethoxycoumarin O-deethylations, CYP2C8-dependent taxol 6α-hydroxylation and CYP2C19-dependent R-warfarin 7-hydroxylation. This chemical also inhibited slightly the xenobiotic oxidations catalysed by CYP1B1, 2B6, 2C9, 2D6, 2E1 and 3A4 in recombinant enzyme systems. 3. Retinol, retinoic acid and cholecalciferol were strong inhibitors for xenobiotic oxidations catalysed by recombinant CYP1A1, 2C8 and 2C19. 4. Dixon plots of inhibitions of CYP1A1-, 1A2-, 2C8- and 2C19-dependent xenobiotic oxidations by arachidonic acid, of CYP1A1-, 2B6- and 2C19-dependent activities by retinol, and of CYP1A1- and 2C19-dependent activities by cholecalciferol indicated that these chemicals inhibit P450 activities mainly through a competitive mechanism. 5. In human liver microsomes, arachidonic acid inhibited CYP1A2-dependent theophylline hydroxylation, CYP2C8-dependent taxol 6α-hydroxylation and CYP2C19-dependent omeprazole 5-hydroxylation. Taxol 6α-hydroxylation was also inhibited by retinol and retinoic acid, and omeprazole 5-hydroxylation was inhibited by retinol in human liver microsomes. 6. These results suggest that xenobiotic oxidations by P450 enzymes are affected by endobiotic chemicals and that the endobiotic-xenobiotic interactions as well as drug-drug interactions may be of great importance when understanding the basis for pharmacological and toxicological actions of a number of xenobiotic chemicals.